Technical Analysis for BGNE - BeiGene, Ltd.

Grade Last Price % Change Price Change
D 298.135 -5.93% -18.80
BGNE closed down 1.49 percent on Friday, July 23, 2021, on 1.83 times normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical BGNE trend table...

Date Alert Name Type % Chg
200 DMA Support Bullish -5.93%
Inside Day Range Contraction -5.93%
Slingshot Bearish Bearish Swing Setup -7.33%
Crossed Above 200 DMA Bullish -7.33%
Cup with Handle Other -7.33%
Outside Day Range Expansion -7.33%
Fell Below 200 DMA Bearish -2.77%
Stochastic Reached Oversold Weakness -2.77%
Down 3 Days in a Row Weakness -2.77%
Down 4 Days in a Row Weakness -2.77%
Older End-of-Day Signals for BGNE ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Gap Down Partially Closed 12 minutes ago
Gapped Down (Full) 12 minutes ago
Down 3% 12 minutes ago
Down 2 % 12 minutes ago
Down 1% 12 minutes ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

BeiGene, Ltd. Description

BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops various oncology drugs in the People's Republic of China. The company's clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers. Its preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company was founded in 2010 and is based in Camana Bay, Cayman Islands.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancers Monoclonal Antibody Monoclonal Antibodies Lymphoma Oncogenes Protein Kinase Kras Humanized Antibody Ras Subfamily Bruton's Tyrosine Kinase Recombination Rp1

Is BGNE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 388.97
52 Week Low 204.17
Average Volume 166,610
200-Day Moving Average 313.64
50-Day Moving Average 337.61
20-Day Moving Average 331.71
10-Day Moving Average 323.56
Average True Range 12.30
ADX 20.85
+DI 14.17
-DI 27.22
Chandelier Exit (Long, 3 ATRs) 330.89
Chandelier Exit (Short, 3 ATRs) 341.08
Upper Bollinger Bands 362.18
Lower Bollinger Band 301.24
Percent B (%b) 0.26
BandWidth 18.37
MACD Line -6.04
MACD Signal Line -4.45
MACD Histogram -1.5987
Fundamentals Value
Market Cap 28.82 Billion
Num Shares 90.9 Million
EPS -11.29
Price-to-Earnings (P/E) Ratio -28.08
Price-to-Sales 63.24
Price-to-Book 4.69
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 331.21
Resistance 3 (R3) 330.29 324.60 328.83
Resistance 2 (R2) 324.60 320.96 325.06 328.04
Resistance 1 (R1) 320.77 318.72 322.68 321.69 327.24
Pivot Point 315.08 315.08 316.04 315.54 315.08
Support 1 (S1) 311.25 311.44 313.16 312.17 306.62
Support 2 (S2) 305.56 309.20 306.02 305.82
Support 3 (S3) 301.73 305.56 305.03
Support 4 (S4) 302.65